<DOC>
	<DOCNO>NCT01867086</DOCNO>
	<brief_summary>This Phase II study Vigil™ autologous tumor cell vaccine integrate carboplatinum . All patient Vigil™ prepare stored ovarian tumor cell obtain time primary surgical debulking . Patients meet eligibility criterion receive either carboplatinum alone ( AUC 6/30 minute infusion ) carboplatinum ( AUC 5/30 minute infusion ) taxol ( 175 mg/m2/3 hour infusion ) one day prior Vigil™ 1.0 x 10e7 cells/intradermal injection , every 3 week .</brief_summary>
	<brief_title>Salvage Ovarian FANG™ Vaccine + Carboplatinum</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Modafinil</mesh_term>
	<mesh_term>Armodafinil</mesh_term>
	<criteria>1 . Histologically confirm papillary serous endometrioid ovarian cancer . 2 . Previous randomization Gradalis , Inc. protocol CLPTL 105 ; observation arm ( Group B ) patient vaccine prepared CLPTL 105 otherwise qualify . 3 . Recurrent cisplatinumsensitive disease ( defined appearance measurable evaluable lesion asymptomatic CA125 level great 100 u/mL two consecutive measurement 6 month period platinum treatment . 4 . Successful manufacture 4 vial Vigil™ vaccine . 5 . Recovered clinically relevant toxicity relate prior therapy . 6 . ECOG PS 02 prior Vigil™ vaccine administration . 7 . Normal organ marrow function define : 1 . Absolute granulocyte count ≥ 1,500/mm3 2 . Absolute lymphocyte count ≥ 200/mm3 3 . Platelets ≥ 100,000/mm3 4 . Total bilirubin ≤ 1.5 x ULN 5 . AST ( SGOT ) /ALT ( SGPT ) /alkaline phosphatase ≤ 2.5 x ULN 6 . Creatinine &lt; 1.5 mg/dL 8 . Patients must `` statin '' drug ≥ 2 week prior initiation therapy . 9 . Ability understand willingness sign write inform protocol specific consent . 1 . Surgery involve general anesthesia , chemotherapy , radiotherapy , steroid therapy , immunotherapy within 4 week prior vaccination . Chemotherapy within 3 week prior vaccination . Steroid therapy within 1 week prior vaccination . 2 . Patient must receive investigational agent within 4 week prior study entry . 3 . Patients require parenteral hydration nutrition evidence partial bowel obstruction perforation . 4 . Patients history brain metastasis . 5 . Patients compromise pulmonary disease . 6 . Short term ( &lt; 30 day ) concurrent systemic steroid ≤ 0.25 mg/kg prednisone per day ( maximum 7.5 mg/day ) bronchodilator ( inhaled steroid ) permit ; steroid regimen and/or immunosuppressive exclude . 7 . Prior splenectomy . 8 . Prior malignancy ( exclude nonmelanoma carcinomas skin carcinoma situ cervix ) unless remission ≥ 2 year . 9 . Kaposi 's Sarcoma . 10 . Patients peripheral neuropathy ≥2 ( paclitaxel ) . 11 . Uncontrolled infection psychiatric illness/social situation would limit compliance study requirement . 12 . Patients know HIV . 13 . Patients chronic Hepatitis B C infection . 14 . Patients uncontrolled autoimmune disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>ovarian cancer</keyword>
</DOC>